Humulin 30/70 (Miscela) (Insulin Human)

Humulin 30/70 is indicated for the management of blood glucose in patients with diabetes mellitus.

• Type 1 diabetes mellitus requiring basal and mealtime insulin.
• Type 2 diabetes mellitus when combined basal and prandial coverage is needed.
• Adults and children (≥2 years) who can safely handle premixed insulin.
• Situations where a single daily injection simplifies the regimen.
• Use as part of a comprehensive diabetes care plan that includes diet, exercise, and glucose monitoring.

• Humulin 30/70 contains human insulin molecules that bind to insulin receptors on muscle, adipose, and hepatic cells. Receptor activation triggers the tyrosine kinase pathway, promoting translocation of GLUT‑4 transporters to the cell surface, which increases glucose uptake. The rapid‑acting component reduces post‑prandial glucose, while the intermediate‑acting component suppresses hepatic glucose production, providing basal insulin coverage. The combined formulation yields a biphasic insulin profile that aligns with typical meal patterns and overnight basal needs.

Like all insulin preparations, Humulin 30/70 may be associated with adverse reactions. Reported events range from mild and transient to rare but serious.

Common

• Mild to moderate hypoglycemia, characterized by shakiness, sweating, or hunger.
• Localized redness, swelling, itching, or bruising at the injection site.
• Lipodystrophy, presenting as small areas of fat loss or accumulation under the skin.
• Gradual weight increase, often related to improved glycemic control.

Serious

• Severe hypoglycemia leading to confusion, loss of consciousness, or seizures.
• Allergic reactions such as widespread rash, urticaria, angio‑edema, or anaphylactic shock.
• Fluid retention or peripheral edema that may worsen heart failure.

Before initiating Humulin 30/70, certain precautions should be considered to minimize risks and ensure safe use.

• Assess renal and hepatic function, as impairment may alter insulin clearance.
• Review history of hypoglycemia unawareness or frequent low glucose episodes.
• Adjust dose when starting or stopping concomitant glucocorticoids, beta‑blockers, or other agents affecting glucose.
• Use caution in pregnant or breastfeeding individuals; discuss risks with a healthcare provider.
• Monitor for signs of cardiovascular disease, especially in patients with edema or heart failure.
• Educate patients on proper injection technique and site rotation.
• Ensure regular blood glucose monitoring and dose adjustments as needed.

Humulin 30/70 can interact with several medications, affecting glucose levels or insulin action.

Avoid

• Concurrent use of other rapid‑acting insulins or insulin analogues without dose adjustment.
• MAO‑B inhibitors (e.g., selegiline) that may potentiate hypoglycemia.

Use with caution

• Beta‑blockers, which may mask hypoglycemia symptoms.
• Corticosteroids, which can increase insulin requirements.
• Thiazide diuretics, which may raise blood glucose.
• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase hypoglycemia risk.
• Alcohol, which can cause delayed hypoglycemia.